GLP-1 Receptor Agonists in Research: How GLP-1 S, Semaglutide, Tirzepatide, and Retatrutide Compare

GLP-1 receptor agonists are among the most heavily studied peptides in modern metabolic research. Over the last decade the field has moved from single-receptor compounds to dual- and even triple-receptor agonists, each generating a large body of peer-reviewed literature on glucose regulation and body-weight models. This primer maps that landscape — what a GLP-1 receptor agonist actually is, how the major research compounds differ, and where GLP-1 S sits within the class.

For laboratory and research use only. The compounds discussed are research chemicals; nothing below is medical advice or a recommendation for human or veterinary use.

What Is a GLP-1 Receptor Agonist?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone. A GLP-1 receptor agonist is a molecule that binds and activates the GLP-1 receptor, reproducing several downstream signaling effects that GLP-1 itself triggers. In the published literature, GLP-1 receptor activation is associated with glucose-dependent insulin secretion, suppression of glucagon release, slowed gastric emptying, and central effects on appetite-regulating neurons in the hypothalamus and hindbrain. Because the receptor is expressed in multiple tissues, GLP-1 receptor agonists have become a core tool for studying metabolic signaling.

The Single → Dual → Triple Agonist Spectrum

The defining trend in this research area is the progressive addition of receptor targets. Compounds are often grouped by how many incretin and metabolic receptors they engage:

• Single agonist — the semaglutide class (GLP-1 only). These engage the GLP-1 receptor alone. Semaglutide is the most-studied example; in the STEP-1 trial, once-weekly semaglutide produced a mean body-weight change of roughly −14.9% versus −2.4% for placebo over 68 weeks. GLP-1 S belongs to this single-agonist, semaglutide class of GLP-1 receptor agonist research peptides.
• Dual agonist — the tirzepatide class (GLP-1 + GIP). Adding glucose-dependent insulinotropic polypeptide (GIP) activity defines the dual agonists. In SURMOUNT-1, tirzepatide showed mean body-weight reductions of about −15.0% to −20.9% across ascending dose arms versus −3.1% for placebo. In our catalog, GLP-2 Tirz is the dual-agonist research compound in this family.
• Triple agonist — retatrutide (GLP-1 + GIP + glucagon). The newest tier adds glucagon-receptor activity on top of GLP-1 and GIP. In its phase 2 trial, retatrutide produced a mean body-weight change of −24.2% at the highest dose arm over 48 weeks — the largest reported in this compound class at the time of publication. Retatrutide is available as a research compound, and we cover it in depth in its own explainer.

Where GLP-1 S Fits

GLP-1 S is a single-receptor, GLP-1 agonist research peptide — the same broad class as semaglutide. In research contexts it is studied for GLP-1 receptor signaling, glucose regulation, and body-weight models, and it is supplied as a 20 mg lyophilized powder strictly for laboratory use. For researchers building a comparative study across the incretin spectrum, GLP-1 S represents the single-agonist baseline against which dual (GLP-2 Tirz) and triple (Retatrutide) compounds can be contrasted.

What the Literature Actually Measures

Across these compounds, the published research consistently reports on a shared set of endpoints: fasting and post-prandial glucose, insulin and glucagon dynamics, gastric-emptying rate, food-intake and body-weight models, and downstream metabolic markers. Understanding that these are the standard measured variables helps researchers design experiments comparable to the existing body of work. This literature is drawn from controlled clinical and preclinical studies; it describes what has been observed in those settings, not a protocol for any other use.

Sourcing Considerations for Research

Because GLP-1 receptor agonists are peptides supplied as lyophilized powder, two factors matter most for reproducible research: purity and documentation. Every Golden State Bio lot ships with a third-party certificate of analysis (CoA) so the identity and purity of the material are verifiable before it enters a study. All compounds are sold for laboratory and research use only — not for human or veterinary use.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is a peptide that binds and activates the GLP-1 receptor, reproducing signaling effects associated in research with glucose-dependent insulin secretion, reduced glucagon release, slowed gastric emptying, and appetite regulation. GLP-1 S is a research-grade example, supplied for laboratory use only.

How does GLP-1 S relate to semaglutide?

GLP-1 S belongs to the same single-agonist, semaglutide class of GLP-1 receptor agonist research peptides — compounds that engage the GLP-1 receptor alone. It is supplied strictly for laboratory and research use, not for human or veterinary use.

What is the difference between single, dual, and triple agonists?

A single agonist engages the GLP-1 receptor (semaglutide class, including GLP-1 S). A dual agonist adds the GIP receptor (tirzepatide class, including GLP-2 Tirz). A triple agonist adds the glucagon receptor on top of both (retatrutide). Each tier is studied for progressively different effects in glucose and body-weight models.

Is GLP-1 S third-party tested?

Yes — every lot ships with a certificate of analysis (CoA) confirming identity and purity by third-party testing. Research use only; not for human or veterinary use.

Is GLP-1 S approved for human use?

No. GLP-1 S is a research compound supplied for laboratory use only. It is not a medicine, is not approved for human or veterinary use, and nothing here is medical advice.